ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
40 003,59
0,34%
DAX
18 704,42
-0,11%
Brent Oil
83,835
0,29%
Bitcoin
66 703,00
0,65%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Savara Inc (SVRA)

  7. Savara Inc (SVRA) Actualités

SVRA

Savara (SVRA)

Savara Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:SVRA
DateHeureSourceTitreSymboleSociété
19/05/202418h15Business WireSavara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024NASDAQ:SVRASavara Inc
16/05/202422h05Business WireSavara Announces New Employment Inducement GrantNASDAQ:SVRASavara Inc
09/05/202422h46Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SVRASavara Inc
09/05/202422h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SVRASavara Inc
09/05/202422h05Business WireSavara Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:SVRASavara Inc
07/05/202422h05Business WireSavara to Present at the Citizens JMP Life Sciences ConferenceNASDAQ:SVRASavara Inc
08/04/202414h05Business WireSavara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024NASDAQ:SVRASavara Inc
07/03/202422h26Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SVRASavara Inc
07/03/202422h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SVRASavara Inc
07/03/202422h05Business WireSavara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business UpdateNASDAQ:SVRASavara Inc
06/03/202422h05Business WireSavara to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:SVRASavara Inc
16/02/202414h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SVRASavara Inc
15/02/202402h35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SVRASavara Inc
31/01/202420h08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SVRASavara Inc
31/01/202414h05Business WireSavara to Present at Two Upcoming Healthcare ConferencesNASDAQ:SVRASavara Inc
29/12/202322h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SVRASavara Inc
28/12/202322h29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SVRASavara Inc
21/12/202314h05Business WireSavara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NASDAQ:SVRASavara Inc
20/12/202314h05Business WireSavara Added to the NASDAQ Biotechnology IndexNASDAQ:SVRASavara Inc
21/11/202314h05Business WireSavara to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:SVRASavara Inc
09/11/202322h05Business WireSavara Reports Third Quarter Financial Results and Provides Business UpdateNASDAQ:SVRASavara Inc
08/11/202322h05Business WireSavara to Present at the Jefferies London Healthcare ConferenceNASDAQ:SVRASavara Inc
05/09/202322h05Business WireSavara to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:SVRASavara Inc
10/08/202322h05Business WireSavara Reports Second Quarter Financial Results and Provides Business UpdateNASDAQ:SVRASavara Inc
26/07/202322h57Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SVRASavara Inc
13/07/202323h17Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SVRASavara Inc
13/07/202313h00Business WireSavara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsNASDAQ:SVRASavara Inc
26/06/202322h05Business WireSavara Added to Russell 3000® IndexNASDAQ:SVRASavara Inc
26/06/202314h05Business WireSavara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)NASDAQ:SVRASavara Inc
16/06/202322h18Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SVRASavara Inc
 Showing the most relevant articles for your search:NASDAQ:SVRA

Dernières Valeurs Consultées

LSE
BU79
Mitsu Hc Cap.27
LSE
FAAN
Faang+
GATE
SBRETH
Saber Protocol Token
USOTC
SGGDF
Sage Gold (CE)
LSE
82CG
Westpac 43
EU
SGENG
Euronext G Engie 261021 ...
LSE
DPD
AMEX
DON
WisdomTree US MidCap Div...
LSE
34MW
Sg Issuer 31
LSE
QJ57
Morg.st.b.v 26
NYSE
IFIN.WS
InFinT Acquisition
BOV
JBSS3
JBS ON
USOTC
DTRK
DataTRAK (PK)
ASX
WRMOB
White Rock Minerals
LSE
88FV
Westpac 25 (s)
EU
3JD
Leverage
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés